[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,949,408
  • Shares Outstanding, K 2,042,071
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,521 M
  • EBITDA $ 16,532 M
  • 60-Month Beta 0.24
  • Price/Sales 2.40
  • Price/Cash Flow 6.96
  • Price/Book 5.75

Options Overview Details

View History
  • Implied Volatility 29.59% (+2.04%)
  • Historical Volatility 28.57%
  • IV Percentile 47%
  • IV Rank 44.54%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 4) 1.70 (2.97%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 30,180
  • Volume Avg (30-Day) 25,421
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 711,464
  • Open Int (30-Day) 625,515
  • Expected Range 55.57 to 58.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.61
  • Number of Estimates 10
  • High Estimate $1.71
  • Low Estimate $1.53
  • Prior Year $1.46
  • Growth Rate Est. (year over year) +10.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.20 +5.66%
on 06/02/26
60.25 -4.95%
on 05/22/26
+0.32 (+0.56%)
since 05/05/26
3-Month
54.20 +5.66%
on 06/02/26
62.22 -7.96%
on 04/01/26
-3.47 (-5.71%)
since 03/05/26
52-Week
42.52 +34.69%
on 10/29/25
62.89 -8.93%
on 03/02/26
+9.43 (+19.71%)
since 06/05/25

Most Recent Stories

More News
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions ...

BMY : 57.27 (+1.18%)
3 Value Stocks We Think Twice About

3 Value Stocks We Think Twice About

MTG : 25.51 (+1.55%)
ICFI : 69.88 (+1.57%)
BMY : 57.27 (+1.18%)
Is Bristol-Myers Squibb Stock Underperforming the Dow?

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

LLY : 1,131.42 (+0.55%)
$DOWI : 50,866.78 (-1.35%)
BMY : 57.27 (+1.18%)
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO ® 2026 ...

BMY : 57.27 (+1.18%)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population ...

BMY : 57.27 (+1.18%)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL)

BMY : 57.27 (+1.18%)
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

BMY : 57.27 (+1.18%)
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

First Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO ® 2026 SUCCESSOR-2 data reinforce...

BMY : 57.27 (+1.18%)
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026. ...

BMY : 57.27 (+1.18%)
1 Surging Stock with Promising Prospects and 2 We Ignore

1 Surging Stock with Promising Prospects and 2 We Ignore

KO : 79.48 (+3.46%)
VSH : 57.20 (-10.16%)
BMY : 57.27 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 58.82
2nd Resistance Point 58.32
1st Resistance Point 57.79
Last Price 57.27
1st Support Level 56.77
2nd Support Level 56.27
3rd Support Level 55.74

See More

52-Week High 62.89
Last Price 57.27
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.